VAERS Explorer
Back to explore

Report #2891253

Received Mar 31, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
19 yrs
State
NJ
Recovered
Unknown
Vaccinated
Jan 7, 2026
Onset
Jan 7, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (ENGERIX-B)GLAXOSMITHKLINE BIOLOGICALSUNK9G523

Symptoms (1)

Incorrect dose administered

Symptom narrative

Adult dose to an adolescent patient/he Vaccine Administration Facility is the same as Primary Reporter", Call Notes:During the conversation, the HCP reported that this was the 1 mL dose, however the lot number 9G523 shows to be for the 0.5 mL. We cal; Adult dose to an adolescent patient/he Vaccine Administration Facility is the same as Primary Reporter", Call Notes:During the conversation, the HCP reported that this was the 1 mL dose, however the lot number 9G523 shows to be for the 0.5 mL. We cal; This non-serious case was reported by a other health professional via call center representative and described the occurrence of overdose in a 19-year-old male patient who received HBV (Engerix B adult) (batch number 9G523) for prophylaxis. On 07-JAN-2026, the patient received Engerix B adult 1 ml. On 07-JAN-2026, an unknown time after receiving Engerix B adult, the patient experienced overdose (Verbatim: Adult dose to an adolescent patient/he Vaccine Administration Facility is the same as Primary Reporter", Call Notes:During the conversation, the HCP reported that this was the 1 mL dose, however the lot number 9G523 shows to be for the 0.5 mL. We cal) and adult product administered to child (Verbatim: Adult dose to an adolescent patient/he Vaccine Administration Facility is the same as Primary Reporter", Call Notes:During the conversation, the HCP reported that this was the 1 mL dose, however the lot number 9G523 shows to be for the 0.5 mL. We cal). The outcome of the overdose and adult product administered to child were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-MAR-2026 The Vaccine Administration Facility had been the same as the Primary Reporter. During the conversation, the HCP had reported that the dose was 1 mL; however, the lot number 9G523 had indicated it was for the 0.5 mL dose. We had called back to clarify this, and the HCP had stated that they had no idea, explaining that it had appeared in their system as an adult dose. The case has been linked with case US2026039678reported by same reporter.; Sender's Comments: US-GSK-US2026039678:SAME REPORTER